 |
Marketing
The Directors consider marketing to be J.Duncan's key strength and concentrate significant resources in this area. The Company has developed extensive databases and obtains regular feedback on customer purchasing patterns and preferences and doctors' prescribing habits. This detailed information is used to direct the Company's promotional spend, sales force activity and product development programmers and to identify new product opportunities. |
| |
|
|
Customer Focus
The ability to retain and expand its customer base is key to the Company's continuous growth and hence the awareness of customer needs and perceptions is instilled throughout the Company with resources dedicated to customer support functions and the active solicitation of customers' views. |
| |
|
|
Product Portfolio Management
J.Duncan has a diverse product portfolio across all Divisions and does not rely on any one product or class of drug for a significant proportion of its revenue. With a strong product development programme, the Company continues to launch products in different segments. |
| |
|
|
 Outsourcing
The Company outsource certain functions, allowing its financial and managerial resources to be concentrated within the areas of greatest added value: marketing and product development. The Directors believe that this policy has enabled the Company to expand more rapidly than would otherwise have been possible and expect to continue to work with business partners in manufacturing, pharmaceutical distribution and elements of research and development. |
| |
|
|
Risk Management
Financial controls provide the management team with detailed and timely performance information, allowing rapid decisions to be taken to enhance or discontinue programmes. Therefore, the Directors can encourage investment and innovation without exposing the Company to undue financial risks. |
| |
|
|
Investment in People
The Directors consider investment in people to be important in the Company. Time and resources are devoted to train at all levels with the aim of instilling a common understanding of J.Duncan's objectives, strategic principles and expected staff performance levels, as well as enhancing individuals' skills. |
| |
|
|
Group Turnover
Depending on the principles of product development and strategies on marketing of prescription and healthcare products, the turnover of the group in the year 2006-2007 was just above Rs. 30 million. There are concrete strategies in place which will assure to boost a growth rate of over minimum 55% in the current financial year 2007-2008. |
| |
|
|
 Manufacturing Faccility
The Company has strong technical team who are capable of providing best of the medicines. Accordingly, the Company has planned to start their manufacturing set up at 65-67, Atgaon Industrial Complex, Atgaon, Shahpur, District Thane (Maharashtra), which is a very ultra modern plant with all the best facility available for manufacturing as per international standards and WHO-GMP norms. The plant is likely to commence its activity in July 2007 with the facility of oral dosages viz Tablets, Capsules, Liquids and Soft Gelatin Capsules. The expected cost for the plant is approximately Rs. 80 million. |
| |
|
